OverviewChartNewsTraderScreen

Ocuphire Pharma Inc/  US67577R1023  /

IEX
2024-05-22  9:57:20 PM Chg. +0.03 Volume Bid- Ask- High Low
1.77USD +1.72% 540
Turnover: 970.07		 -Bid Size: - -Ask Size: - 1.81 1.77
GlobeNewswire 05-10 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire 05-06 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
GlobeNewswire 05-03 Ocuphire Pharma to Present at the Aegis Virtual Conference
GlobeNewswire 04-22 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
GlobeNewswire 04-11 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire 04-01 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire 03-08 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
GlobeNewswire 02-23 Ocuphire Pharma to Present in the BIO CEO & Investor Conference
GlobeNewswire 02-15 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 02-14 Ocuphire Pharma Strengthens Leadership Team with Key Appointments
GlobeNewswire 02-05 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire 01-24 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 01-04 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire 2023-11-30 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire 2023-11-27 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2023-11-27 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
GlobeNewswire 2023-11-13 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
GlobeNewswire 2023-11-02 Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Re...
GlobeNewswire 2023-11-01 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2023-11-01 Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Offi...
GlobeNewswire 2023-10-26 Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
GlobeNewswire 2023-10-06 Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
GlobeNewswire 2023-09-27 Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.7...
GlobeNewswire 2023-09-11 Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
GlobeNewswire 2023-09-07 Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September